This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Bacterial Infections  • Drug Therapy, Other  • Alert me on articles by topic

Pierre Tattevin, MD; Cédric Arvieux, MD; Christian Michelet, MD, PhD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In a recently published article, Hidayat et al¹ observed a high prevalence of clinical methicillin-resistant Staphylococcus aureus (MRSA) strains with an elevated vancomycin minimum inhibitory concentration (2 µg/mL) in a prospective cohort, and they studied treatment outcomes with high-dose vancomycin hydrochloride. The authors concluded that (1) these strains require aggressive empirical vancomycin dosing to achieve trough plasma concentrations greater than 15 µg/mL and (2) combination or alternative therapy should be considered for invasive infections caused by these strains.¹ Although they provide convincing data supporting the first part of this conclusion, the reader may feel disappointed with the data supporting the second part (ie, the place of combination or alternative therapy). Indeed, of the 95 patients included in this study, only 15 received vancomycin in combination with linezolid, daptomycin, and/or rifampin, and the only information we have about them from this . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED ARTICLE

High-Dose Vancomycin Therapy for Methicillin-Resistant Staphylococcus aureus Infections: Efficacy and Toxicity
Levita K. Hidayat, Donald I. Hsu, Ryan Quist, Kimberly A. Shriner, and Annie Wong-Beringer
Arch Intern Med. 2006;166(19):2138-2144.
ABSTRACT | FULL TEXT